Pharmaceutical

AlzeCure Selects Drug Candidate and Enters Next Phase of Development with TrkA-NAM ACD137 against Severe Pain

STOCKHOLM, SWEDEN / ACCESSWIRE / January 29, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR, a…

11 months ago

Daré Bioscience Announces Executive Team and Board of Directors Changes

SAN DIEGO, Jan. 26, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today…

11 months ago

AB Science announces an update in the marketing authorization application of masitinib in amyotrophic lateral sclerosis at the European Medicines Agency

PRESS RELEASE AB SCIENCE ANNOUNCES AN UPDATE IN THE MARKETING AUTHORIZATION APPLICATION OF MASITINIB IN AMYOTROPHIC LATERAL SCLEROSIS AT THE…

11 months ago

Processa Pharmaceuticals Announces Pricing of $7.0 Million Public Offering

HANOVER, Md., Jan. 26, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical…

11 months ago

ObjectiveHealth Announces Strategic Growth Investment from Vitruvian Partners

NASHVILLE, Tenn.--(BUSINESS WIRE)--#centersofexcellence--ObjectiveHealth, a leading integrated specialty research network and technology company, announced today that it has secured a strategic…

11 months ago

Unexpected Inspiration for More Sustainable Drug Development at Merck

NORTHAMPTON, MA / ACCESSWIRE / January 26, 2024 / Inspiration for a greener world can come from unexpected places. For…

11 months ago

Nutriband CEO Publishes Letter to Shareholders

ORLANDO, FL / ACCESSWIRE / January 26, 2024 / Nutriband Inc. ("Company") (NASDAQ:NTRB)(NASDAQ:NTRBW) today announced that CEO Gareth Sheridan has…

11 months ago

GRI Bio Announces Reverse Stock Split

GRI’s common stock is expected to begin trading on a post-split adjusted basis on January 30, 2024 LA JOLLA, CA,…

11 months ago

Aptose Announces Pricing of $8.4 Million Public Offering and a Concurrent $4 Million Private Placement with Hanmi Pharmaceutical

SAN DIEGO and TORONTO, Jan. 26, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (Nasdaq: APTO, TSX:…

11 months ago

CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting Antibody Drug Conjugate Demonstrates Encouraging Safety and Efficacy in Patients with Nectin-4 Positive Tumors in First-In-Human Study Presented at ASCO-GU 2024

Q3W schedule of CRB-701 (SYS6002) demonstrates a 43% ORR and 71% DCR at predicted therapeutically relevant dosesAll assessable nectin-4 positive…

11 months ago